Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CPB1 | P15086 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15665799 | 0.87 | ALDH1A1 (0.44) | SMN1; SMN2CYP3A4ALDH1A1NPC1RAB9A | |
| SCHEMBL15665561 | 0.87 | ALDH1A1 (0.44) | SMN1; SMN2CYP3A4ALDH1A1NPC1RAB9A | |
| SCHEMBL8723700 | 0.84 | ALDH1A1 (0.43) | SMN1; SMN2CYP3A4ALDH1A1NPC1RAB9A | |
| SCHEMBL1806227 | 0.74 | SMN1; SMN2 (0.45) | SMN1; SMN2CYP3A4ALDH1A1NPC1RAB9A | |
| SCHEMBL6285067 | 0.73 | CPB1 (0.44) | SMN1; SMN2CYP3A4LMNAALDH1A1NPC1 | |
| SCHEMBL2438026 | 0.70 | CPB1 (0.41) | SMN1; SMN2CYP3A4ALDH1A1NPC1RAB9A | |
| SCHEMBL13317580 | 0.70 | ALDH1A1 (0.51) | SMN1; SMN2CYP3A4LMNAALDH1A1NPC1 | |
| SCHEMBL3295119 | 0.69 | CYP2C19 (0.45) | SMN1; SMN2CYP3A4ALDH1A1NPC1RAB9A | |
| SCHEMBL18281695 | 0.69 | KMT2A (0.43) | SMN1; SMN2CYP3A4LMNAALDH1A1NPC1 | |
| SCHEMBL696626 | 0.69 | CYP3A4 (0.40) | SMN1; SMN2CYP3A4ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1527051-B1 | PYRIMIDYL SULPHONE AMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2012-09-12 | — | — | EP | disclosed |
| US-8106063-B2 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2012-01-31 | — | — | US | disclosed |
| US-20100063079-A1 | Pyrimidyl Sulphone Amide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2010-03-11 | — | — | US | disclosed |
| US-7582644-B2 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2009-09-01 | — | — | US | disclosed |
| US-20060025432-A1 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063079-A1 | Pyrimidyl Sulphone Amide Derivatives as Chemokine Receptor Modulators | ACKR3, GPR17, CCL11 | SMN1; SMN2 3600/4885CYP3A4 2456/4885LMNA 4818/4885 |
| US-20060025432-A1 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ACKR3, GPR17, CCL11 | SMN1; SMN2 3600/4885CYP3A4 2456/4885LMNA 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.